{"id":93124,"date":"2026-04-07T15:03:00","date_gmt":"2026-04-07T13:03:00","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=93124"},"modified":"2026-04-07T15:30:05","modified_gmt":"2026-04-07T13:30:05","slug":"andera-partners-portfolio-company-tubulis-acquired-by-gilead-adding-a-potentially-best-in-class-antibody-drug-conjugate-and-a-next-generation-platform-to-gileads-oncology-pipeline","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-tubulis-acquired-by-gilead-adding-a-potentially-best-in-class-antibody-drug-conjugate-and-a-next-generation-platform-to-gileads-oncology-pipeline\/","title":{"rendered":"Andera Partners portfolio company, Tubulis, acquired by Gilead, adding a potentially best-in-class antibody-drug conjugate and a next-generation platform to Gilead\u2019s oncology pipeline."},"content":{"rendered":"<p>Andera Partners today announced that Gilead Sciences, Inc. (Nasdaq: GILD) has entered into a definitive agreement to acquire Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs).<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p>The acquisition significantly expands Gilead\u2019s ADC capabilities by adding next-generation assets and platforms designed to more selectively deliver diverse payloads to tumors and maximize patient benefit. Tubulis\u2019 lead asset, TUB-040, a NaPi2b-directed topoisomerase-I inhibitor (TOPO1i) ADC, is currently in Phase 1b\/2 development for platinum-resistant ovarian cancer and non-small cell lung cancer (NSCLC). Gilead will also acquire TUB-030, a 5T4 targeted ADC, which has demonstrated promising initial clinical data across various solid tumor types. Tubulis\u2019 programs and platforms have broad potential across multiple tumor types, complementing Gilead\u2019s existing development and commercialization expertise in oncology.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p>\u201cFrom the outset, we believed our conjugation technology platforms could have broad impact across the ADC field and the initial data from TUB-040 have reinforced that conviction,\u201d said<strong> Dominik Schumacher, PhD, Chief Executive Officer and Co-founder of Tubulis.<\/strong> \u201cJoining Gilead allows us to build on this foundation within an organization that brings deep scientific expertise, global development capabilities, and the scale needed to translate innovation into medicines for patients worldwide. Through our existing collaboration, Gilead has already seen the potential of our technologies and together, we are well positioned to accelerate the development of our ADC pipeline. I\u2019m deeply grateful to the Tubulis team, our Board of Directors, investors, and partners for their commitment and helping make this milestone possible.\u201d<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p>\u201cWe are extremely proud to have supported Dominik and his team since leading the Series B round of Tubulis in 2022. This acquisition is a testament to the promise of Tubulis\u2019 technologies and pipeline, the vision of the team, and their impeccable execution. Congratulations to the Tubulis team for building a truly transformative ADC company and bringing their innovations closer to patients.\u201d comments <strong>Sofia Ioannidou, Partner at Andera Partners.<\/strong><\/p>\n<p>Following the close of the transaction, Tubulis will operate as a dedicated ADC research organization within Gilead, with the Munich site serving as a hub for ADC innovation, building on its integrated discovery, manufacturing and clinical capabilities to advance next generation ADCs.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p>&nbsp;<\/p>\n<p><b>Terms of the Transaction<span class=\"Apple-converted-space\">\u00a0<\/span><\/b><\/p>\n<p>Under the terms of the sale and purchase agreement, Gilead will acquire all of the outstanding equity of Tubulis for $3.15 billion in upfront cash consideration on a cash-free, debt-free basis, subject to customary adjustments, which is payable at closing, and up to $1.85 billion in contingent milestone payments. Closing of the transaction is subject to expiration or termination of certain regulatory filings and other customary conditions. The transaction is expected to close in the second quarter of 2026. Gilead plans to finance the transaction with a combination of cash on hand and senior unsecured notes.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p>Centerview Partners LLC and Allen &amp; Company LLC are acting as financial advisors for Gilead. J.P. Morgan Securities LLC is acting as the exclusive financial advisor for Tubulis. Covington &amp; Burling LLP, Arnold &amp; Porter LLP, and Venable LLP are serving as legal counsel to Gilead. Goodwin Procter LLP and CMS Hasche Sigle are serving as legal counsel to Tubulis.<span class=\"Apple-converted-space\">\u00a0<\/span><\/p>\n<p><strong><span class=\"Apple-converted-space\">\u00a0<\/span><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Andera Partners today announced that Gilead Sciences, Inc. (Nasdaq: GILD) has entered into a definitive agreement to acquire Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs).\u00a0 The acquisition significantly expands Gilead\u2019s ADC capabilities by adding next-generation assets and platforms designed to more selectively deliver diverse payloads to tumors and maximize&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-93124","post","type-post","status-publish","format-standard","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Andera Partners portfolio company, Tubulis, acquired by Gilead, adding a potentially best-in-class antibody-drug conjugate and a next-generation platform to Gilead\u2019s oncology pipeline. - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-tubulis-acquired-by-gilead-adding-a-potentially-best-in-class-antibody-drug-conjugate-and-a-next-generation-platform-to-gileads-oncology-pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Andera Partners portfolio company, Tubulis, acquired by Gilead, adding a potentially best-in-class antibody-drug conjugate and a next-generation platform to Gilead\u2019s oncology pipeline. - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"Andera Partners today announced that Gilead Sciences, Inc. (Nasdaq: GILD) has entered into a definitive agreement to acquire Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs).\u00a0 The acquisition significantly expands Gilead\u2019s ADC capabilities by adding next-generation assets and platforms designed to more selectively deliver diverse payloads to tumors and maximize...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-tubulis-acquired-by-gilead-adding-a-potentially-best-in-class-antibody-drug-conjugate-and-a-next-generation-platform-to-gileads-oncology-pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-07T13:03:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-07T13:30:05+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-tubulis-acquired-by-gilead-adding-a-potentially-best-in-class-antibody-drug-conjugate-and-a-next-generation-platform-to-gileads-oncology-pipeline\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-tubulis-acquired-by-gilead-adding-a-potentially-best-in-class-antibody-drug-conjugate-and-a-next-generation-platform-to-gileads-oncology-pipeline\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Andera Partners portfolio company, Tubulis, acquired by Gilead, adding a potentially best-in-class antibody-drug conjugate and a next-generation platform to Gilead\u2019s oncology pipeline.\",\"datePublished\":\"2026-04-07T13:03:00+00:00\",\"dateModified\":\"2026-04-07T13:30:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-tubulis-acquired-by-gilead-adding-a-potentially-best-in-class-antibody-drug-conjugate-and-a-next-generation-platform-to-gileads-oncology-pipeline\/\"},\"wordCount\":541,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-tubulis-acquired-by-gilead-adding-a-potentially-best-in-class-antibody-drug-conjugate-and-a-next-generation-platform-to-gileads-oncology-pipeline\/\",\"url\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-tubulis-acquired-by-gilead-adding-a-potentially-best-in-class-antibody-drug-conjugate-and-a-next-generation-platform-to-gileads-oncology-pipeline\/\",\"name\":\"Andera Partners portfolio company, Tubulis, acquired by Gilead, adding a potentially best-in-class antibody-drug conjugate and a next-generation platform to Gilead\u2019s oncology pipeline. - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2026-04-07T13:03:00+00:00\",\"dateModified\":\"2026-04-07T13:30:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-tubulis-acquired-by-gilead-adding-a-potentially-best-in-class-antibody-drug-conjugate-and-a-next-generation-platform-to-gileads-oncology-pipeline\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-tubulis-acquired-by-gilead-adding-a-potentially-best-in-class-antibody-drug-conjugate-and-a-next-generation-platform-to-gileads-oncology-pipeline\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-tubulis-acquired-by-gilead-adding-a-potentially-best-in-class-antibody-drug-conjugate-and-a-next-generation-platform-to-gileads-oncology-pipeline\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.anderapartners.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Andera Partners portfolio company, Tubulis, acquired by Gilead, adding a potentially best-in-class antibody-drug conjugate and a next-generation platform to Gilead\u2019s oncology pipeline.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Andera Partners portfolio company, Tubulis, acquired by Gilead, adding a potentially best-in-class antibody-drug conjugate and a next-generation platform to Gilead\u2019s oncology pipeline. - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-tubulis-acquired-by-gilead-adding-a-potentially-best-in-class-antibody-drug-conjugate-and-a-next-generation-platform-to-gileads-oncology-pipeline\/","og_locale":"en_US","og_type":"article","og_title":"Andera Partners portfolio company, Tubulis, acquired by Gilead, adding a potentially best-in-class antibody-drug conjugate and a next-generation platform to Gilead\u2019s oncology pipeline. - ANDERA PARTNERS","og_description":"Andera Partners today announced that Gilead Sciences, Inc. (Nasdaq: GILD) has entered into a definitive agreement to acquire Tubulis GmbH, a private Germany-based, clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs).\u00a0 The acquisition significantly expands Gilead\u2019s ADC capabilities by adding next-generation assets and platforms designed to more selectively deliver diverse payloads to tumors and maximize...","og_url":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-tubulis-acquired-by-gilead-adding-a-potentially-best-in-class-antibody-drug-conjugate-and-a-next-generation-platform-to-gileads-oncology-pipeline\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2026-04-07T13:03:00+00:00","article_modified_time":"2026-04-07T13:30:05+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Nicolas Delsert","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-tubulis-acquired-by-gilead-adding-a-potentially-best-in-class-antibody-drug-conjugate-and-a-next-generation-platform-to-gileads-oncology-pipeline\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-tubulis-acquired-by-gilead-adding-a-potentially-best-in-class-antibody-drug-conjugate-and-a-next-generation-platform-to-gileads-oncology-pipeline\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Andera Partners portfolio company, Tubulis, acquired by Gilead, adding a potentially best-in-class antibody-drug conjugate and a next-generation platform to Gilead\u2019s oncology pipeline.","datePublished":"2026-04-07T13:03:00+00:00","dateModified":"2026-04-07T13:30:05+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-tubulis-acquired-by-gilead-adding-a-potentially-best-in-class-antibody-drug-conjugate-and-a-next-generation-platform-to-gileads-oncology-pipeline\/"},"wordCount":541,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-tubulis-acquired-by-gilead-adding-a-potentially-best-in-class-antibody-drug-conjugate-and-a-next-generation-platform-to-gileads-oncology-pipeline\/","url":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-tubulis-acquired-by-gilead-adding-a-potentially-best-in-class-antibody-drug-conjugate-and-a-next-generation-platform-to-gileads-oncology-pipeline\/","name":"Andera Partners portfolio company, Tubulis, acquired by Gilead, adding a potentially best-in-class antibody-drug conjugate and a next-generation platform to Gilead\u2019s oncology pipeline. - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2026-04-07T13:03:00+00:00","dateModified":"2026-04-07T13:30:05+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-tubulis-acquired-by-gilead-adding-a-potentially-best-in-class-antibody-drug-conjugate-and-a-next-generation-platform-to-gileads-oncology-pipeline\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-tubulis-acquired-by-gilead-adding-a-potentially-best-in-class-antibody-drug-conjugate-and-a-next-generation-platform-to-gileads-oncology-pipeline\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/en\/andera-partners-portfolio-company-tubulis-acquired-by-gilead-adding-a-potentially-best-in-class-antibody-drug-conjugate-and-a-next-generation-platform-to-gileads-oncology-pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.anderapartners.com\/en\/"},{"@type":"ListItem","position":2,"name":"Andera Partners portfolio company, Tubulis, acquired by Gilead, adding a potentially best-in-class antibody-drug conjugate and a next-generation platform to Gilead\u2019s oncology pipeline."}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/93124","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/comments?post=93124"}],"version-history":[{"count":3,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/93124\/revisions"}],"predecessor-version":[{"id":93130,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/posts\/93124\/revisions\/93130"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/media?parent=93124"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/en\/wp-json\/wp\/v2\/categories?post=93124"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}